DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cranial nerve neoplasm — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCranial nerve neoplasm maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cranial nerve neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Forty-six patients with vagal paraganglioma were treated over a 20-year period by a single skull base team. Ten (22%) had intracranial extension. Nine (20%) had a family history of paraganglioma. In patients with familial paraganglioma the rate of multicentric tumours was 78%, compared with 23% in non-familial cases. Management was surgery in 40 patients, radiation therapy in 4, and observation in 2. Postoperative cranial nerve deficits were common. The authors concluded that treatment options are surgical resection, radiation therapy, and, in selected cases, observation, and that radiation is reserved for elderly patients and those at risk for bilateral cranial nerve deficits.
A separate study used ethylnitrosourea to induce trigeminal malignant peripheral nerve sheath tumours (MPNSTs) in rats. These tumours became detectable when they were comparatively small because they caused increased intracranial pressure. Histology showed close resemblance to human MPNSTs. Compared with normal trigeminal nerve, 365 genes were markedly upregulated and 310 consistently downregulated in all tumour samples. The molecular signature included upregulation of proliferation and tissue-remodelling genes, downregulation of Schwann cell differentiation genes, and absence of neuronal transcripts. The transforming growth factor-β pathway was consistently upregulated. The authors suggested that signalling pathways underlying early malignant progression of Schwann cells might be targeted to prevent tumour growth or treat more advanced lesions.
A third paper noted that most malignant human tumours, including MPNSTs and aggressive soft tissue sarcomas, display high intratumoral heterogeneity at diagnosis that contributes to treatment failure. MPNSTs average 10 cm in diameter at diagnosis. The rat model was intended to explore molecular changes present in most tumour cells before such heterogeneity develops.
What is still missing is any clinical trial of a drug for cranial nerve neoplasms in humans. The rat study identified potential molecular targets but did not test any compound. The vagal paraganglioma series reported only surgery and radiation, with no systemic therapy. No data exist on patient stratification by molecular subtype, and no funding for a drug-repurposing trial in these rare tumours has been described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Otolaryngology - Head and Neck Surgery · 1998 · 310 citations
Vagal Paraganglioma
AbstractBACKGROUND: Vagal paragangliomas (VPs) arise from paraganglia associated with the vagus nerve. Approximately 200 cases have been reported in the medical literature. Because of their rarity, most information regarding these tumors has arisen from case reports and small clinical series. OBJECTIVE: To detail the clinicopathologic features of 46 patients with VP with an emphasis on the role of a multidisciplinary skull base team in both the successful extirpation and rehabilitation. DESIGN: Retrospective review of 46 patients with VP managed by a single skull base team. SETTING: An academic tertiary medical center. RESULTS: Forty-six patients were treated over a 20-year period (1978-1998). Ten (22%) demonstrated intracranial extension. There was a history of familial paragangliomas in 9 (20%) of the patients. The incidence of multicentric paragangliomas was 78% in patients with familial paragangliomas vs 23% in patients with nonfamilial paragangliomas. Management of this group of 46 patients consisted of surgery (n = 40), radiation therapy (n = 4), and observation (n = 2). The operative approach consisted of a transcervical excision often combined with a transtemporal or lateral skull base approach as dictated by the tumor extent. Postoperative cranial nerve deficits were common, and, as such, aggressive rehabilitation was a vital component in the management of these tumors. CONCLUSIONS: The management of VP and its associated cranial nerve deficits remains a difficult clinical problem. Options for treatment include surgical resection, radiation therapy, and, in selected cases, observation. Surgical extirpation requires a multidisciplinary skull base team to achieve complete tumor resection. Radiation therapy is reserved for elderly patients and patients at risk for bilateral cranial nerve deficits. Rehabilitation of cranial nerve deficits is an integral part of the management of VP.
Journal of Neuropathology & Experimental Neurology · 2013 · 4 citations · open access
Chemically Induced Rat Schwann Cell Neoplasia as a Model for Early-Stage Human Peripheral Nerve Sheath Tumors: Phenotypic Characteristics and Dysregulated Gene Expression
AbstractMost malignant human tumors display a high degree of intratumoral heterogeneity at the time of diagnosis that contributes to treatment failure. This also applies to malignant peripheral nerve sheath tumors (MPNSTs) and aggressive soft tissue sarcomas that arise sporadically or in the context of neurofibromatosis type 1. On average, MPNSTs measure 10 cm in diameter at diagnosis. To explore molecular changes associated with early malignant progression and that may be present in most, if not all, tumor cells, we generated expression profiles of ethylnitrosourea-induced trigeminal MPNSTs in rats. Because these tumors cause increased intracranial pressure, they become detectable when they are comparatively minuscule. Histologic analyses revealed close resemblance to human MPNSTs. Compared with normal trigeminal nerve tissue, 365 genes were markedly upregulated and 310 genes were consistently downregulated in all MPNST samples. The molecular signature characteristic of early-stage MPNSTs included upregulation of proliferation and tissue remodeling-associated genes, downregulation of genes involved in Schwann cell differentiation, and the absence of transcripts associated with neuronal components. The transforming growth factor-β pathway was consistently upregulated in all tumor samples. These data suggest that the signaling pathways underlying early malignant progression of Schwann cells might be targeted to prevent tumor growth and/or to treat more advanced lesions.
Neurosurgical FOCUS · 2013 · 0 citations · open access
Introduction: Cranial nerve surgery
AbstractIn this issue of Neurosurgical Focus, we have compiled a group of interesting papers related to anatomy, physiology, pathology, and surgery of the cranial nerves. We were very pleased to receive many more submissions of excellent papers on this topic from which we had the difficult task of having to select, because of limitations in space, only 8 papers.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
